Candel Therapeutics, Inc.
CADL
NASDAQ·Healthcare·Biotechnology·Mkt cap $936.4M
$12.78
▼ -1.46%
P/E
-9.06
Mkt Cap
$936.4M
52-Wk Range
$4.35–$14.00
52-Week Range
$4.35 - $14.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 150.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Multi-indication immunotherapy platform with potential for broad cancer applications
- Advanced clinical development stage with Phase III trials underway in prostate cancer
- Focused pipeline addressing high-mortality cancers with limited treatment options
- Experienced management team with oncology and immunotherapy expertise
Bear Case
1 risk
- Low volatility (beta -0.5).
Growth
Stable outlook
Phase III clinical trial progression in prostate cancer with potential for regulatory approval
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+50.4% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CADL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 13, 2026
Reported EPS of -$0.52 vs -$0.24 consensus (-118.5% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-118.5%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 29, 2026
vs Industry
How CADL stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related